Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
INKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.56 - $76.00
Previous CloseN/A
Volume98.55K
Average Volume (3M)110.93K
Market Cap
$69.16M
Enterprise Value$33.24M
Total Cash (Recent Filing)$1.68M
Total Debt (Recent Filing)$5.51M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Oct 30, 2025EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding4,522,927
10 Day Avg. Volume49,285
30 Day Avg. Volume110,930
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit-55.68K
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
$39.00Price Target Upside155.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsA patient with treatment-refractory testicular cancer treated with Opdivo plus agenT-797 in the Phase I trial achieved a complete remission.
Corporate DevelopmentsThe company achieved a Department of Defense STTR Grant and announced a new clinical grant, supporting further research and trials.
Financial And Strategic Planning$50M ATM announced, creating flexibility for necessary cash infusion to support ongoing and new clinical trials.
Bears Say
Financial ConstraintsWith only $3.2 million in cash at the end of the first quarter, financial constraints are a concern.
Stock PerformanceShares of MiNK traded up over 700%, exceeding the previous fair-value estimate, leading to a downgrade to Market Perform.
Stock RatingGiven INKT shares are up over 400%, and the majority of the enthusiasm has been priced in for the near-term, the rating is downgraded to Neutral from Buy.
MiNK Therapeutics News
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $4.56 and its highest was $76.00 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $69.16M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 48 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on Aug 14, 2025. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.547 by -$0.513.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.86.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 4,522,927 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.547. Following the earnings report the stock price went down -12.457%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
MiNK Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (155.07% Upside)
$39.00 (155.07% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.87%
12-Months-Change
Fundamentals
Return on Equity
78.50%
Trailing 12-Months
Asset Growth
-75.93%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
INKT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant clinical progress and operational efficiencies, particularly in iNKT therapies, with strategic partnerships and upcoming trials indicating a positive outlook. However, financial strains such as increased net loss and limited cash reserves present challenges.View all INKT earnings summariesINKT Stock 12 Month Forecast
Average Price Target
$39.00
▲(155.07% Upside)
Technical Analysis
Ownership Overview
3.38% Insiders
0.84% Mutual Funds
0.42% Other Institutional Investors
94.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---